{
    "company_name": "AMPLIA THERAPEUTICS LIMITED",
    "address": "Level 17, 350 Queen Street, MELBOURNE, VIC, AUSTRALIA, 3000",
    "summary": "Pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis.",
    "details": "Pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis.",
    "website": "http://www.ampliatx.com",
    "stock_code": "ATX",
    "links": "['/', 'https://twitter.com/ampliatx', 'https://www.linkedin.com/company/amplia-therapeutics/', 'https://www.youtube.com/channel/UCz3p0MC4CZpnqB63FYZn51w', '/site/content/', '/site/About-Us', '/site/About-Us/company-overview', '/site/About-Us/our-values1', '/site/About-Us/board-of-directors', '/site/About-Us/management', '/site/About-Us/scientific-advisers', '/site/About-Us/clinical-advisers', '/site/About-Us/corporate-directory', '/site/About-Us/corporate-governance', '/site/pipeline', '/site/pipeline/amplias-pipeline', '/site/pipeline/amplias-cancer-program', '/site/pipeline/amplias-fibrosis-program', '/site/clinical-trial', '/site/investor-information', '/site/investor-information/welcome', '/site/investor-information/investor-fact-sheet', '/site/investor-information/current-presentations', '/site/investor-information/media', '/site/investor-information/top-20-shareholders', '/site/investor-information/shareholder-services', '/site/investor-information/investor-faqs', '/site/investor-information/us-shareholders', '/site/news-and-reports', '/site/news-and-reports/ASX-Announcements', '/site/news-and-reports/publications', '/site/news-and-reports/annual-reports', '/site/news-and-reports/half-yearly-reports', '/site/news-and-reports/quarterly-reports', '/site/news-and-reports/research-reports', '/site/contact', '/site/contact/contact-us', '/site/contact/email-alerts1', '/site/amplias-cancer-program', '/site/pipeline/amplias-pipeline', '/site/clinical-trial', '/site/investor-information/current-presentations', '/site/investor-information/current-presentations', '/site/news-and-reports/ASX-Announcements', '/site/media', 'https://www2.asx.com.au/markets/company/atx', '/site/clinical-trial', 'mailto:info@ampliatx.com', 'https://twitter.com/ampliatx', 'https://www.linkedin.com/company/amplia-therapeutics/', 'https://www.youtube.com/channel/UCz3p0MC4CZpnqB63FYZn51w', '/site/utilities/site-map', '/site/utilities/privacy', ' /site/utilities/search', 'https://www.irmau.com']",
    "images": "/site/irmcustomizationfile/75/amplia-logo.png, /site/irmcustomizationfile/75/amplia-logo.png , /site/content/images/asxLogo.png, /site/content/images/irm-logo-small-white.png",
    "company_logo_link": "http://www.ampliatx.com/site/content/images/asxLogo.png"
}